Why fill-finish strategy matters more than ever
Cell and gene therapies are advancing quickly, but for many developers, manufacturing is now one of the biggest barriers to scale. As commercialization becomes more important, process design is now just as crucial as
That shift is also showing up in the regulatory environment. In early 2026, the FDA reinforced its flexible, fit-for-purpose approach to CMC expectations for cell and gene therapies, recognizing that these products require manufacturing strategies built for their unique complexity, variability, and small-batch realities.
One area where this matters most is fill and finish.
For advanced therapies, fill and finish is not simply a final packaging step. It is a quality-critical stage that can influence consistency, product integrity, and comparability across lots. When workflows rely on multiple transfers, disconnected equipment, and manual intervention, risk increases through added variability, contamination exposure, and more fragmented documentation.
That is why there is growing emphasis on closed, integrated fill-finish workflows that reduce handoffs and improve control.
At Xiogenix, this thinking is central to how we design equipment for cell and gene therapy manufacturing. The ARES™ X20+ is a fully closed, automated benchtop system designed to integrate multiple critical process steps into one compact platform, including cooling and homogenization of the source bag, in-process sampling, formulation, air evacuation, and final filling. It supports both bag and vial filling and is designed for cGMP environments with alignment to 21 CFR Part 11 expectations.
This work is also being explored in practice through Cellipont Bioservices’ ongoing study using the Xiogenix ARES™ X20+, focused on advancing closed, automated fill-finish workflows for cell therapy manufacturing. The study reflects a broader industry shift toward process designs that improve consistency, reduce manual variability, and better support regulatory readiness over time.
The message is clear: regulatory flexibility does not reduce the need for rigor. It increases the value of preparedness.
As more cell therapy programs move toward licensure, fill and finish can no longer be treated as an afterthought. It should be designed as a strategic part of the manufacturing process from the start. At Xiogenix, we believe smarter, more integrated fill-finish infrastructure will play an important role in helping advanced therapies move forward with greater consistency, confidence, and readiness for scale to support patients in need.